MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 31, 2024.

The professor of neurology in the department of medicine, surgery, and neuroscience at the University of Siena, gave perspective on an analysis of the MAGNIFY-MS study, in which treatment with cladribine demonstrated impacts on CNS-related pathology in MS. [WATCH TIME: 4 minutes]

Florida-based neurologist Donal Negroski, MD, presents data from an aging MS patient population looking for treatment options under Medicare.

Fred Lublin, MD, the CMSC Presidential Lecture speaker, offers updated views on how to define MS clinical progression.

In comparison with adults on ocrelizumab, pediatric patients experienced no clinical relapses and a safety profile that was similar to what was previously observed.

A recent survey reported a high prevalence of burnout among physicians treating patients with multiple sclerosis, highlighting long work hours as one of the key factors.

Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Within a subgroup of those older than 50 years, most patients who switched to cladribine were relapse free at follow-up, with no new safety signals observed.

The clinical research director of the UCSF Multiple Sclerosis Center talked about results from clinical trials assessing BTK inhibitors in relapsing multiple sclerosis and the ongoing research to explore more effective treatments. [WATCH TIME: 5 minutes]

MS does not carry an increased risk of high-risk pregnancy, but many clinicians are unclear about best practices for managing these patients.

CMSC Kurtzke Lecturer Darin Okuda, MD, demonstrates innovative ways to rethink MRI use in MS.

In a new analysis of the CHIMES trial, ocrelizumab displayed a trend toward improved work productivity among minority patients with relapsing multiple sclerosis.

Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Over a 24-month treatment period, patients on cladribine demonstrated no axonal loss evident on OCT, with reductions in cerebrospinal fluid neurofilament light and impacts on oligoclonal bands.

Nearly half of patients on diphenhydramine, dexamethasone, and famotidine experienced moderate to severe decreased alertness vs only 12.9% of those on cetirizine, dexamethasone, and famotidine.

Over a 5-year treatment period, patients on ofatumumab, regardless of race or ethnicity, demonstrated significant reductions in neurofilament light and achieved consistent rates of NEDA-3.

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.

The associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.

Scott Newsome, DO, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine, provided clarity on the 1-year data of the OCARINA II study assessing subcutaneous ocrelizumab.

Here's some of what is coming soon to NeurologyLive® this week.

The International Journal of MS Care publishes the abstracts for the CMSC Annual Meeting, which is set to be held May 29-June 1, 2024, in Nashville, Tennessee.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

A trio of clinicians from Cleveland Clinic provided perspectives on the advances in neurology seen at the 2024 AAN Annual Meeting, specifically focusing in on epilepsy, stroke, and multiple sclerosis.

The study showed durable improvements in VEP latency with bexarotene, suggesting long-term benefits from exposure to a remyelinating drug.

Here's some of what is coming soon to NeurologyLive® this week.